Case report

Acute immune thrombocytopaenic purpura in a patient with COVID-19 and decompensated cirrhosis

Florent Artru,1 Lorenzo Alberio,2 Darius Moradpour,1 Grégoire Stalder2

SUMMARY

We report on a patient with coronavirus disease 2019 (COVID-19) and decompensated cirrhosis who experienced a favourable outcome of severe immune thrombocytopaenic purpura (ITP) after administration of intravenous immunoglobulin and high-dose dexamethasone. The present case suggests that it is reasonable to evoke ITP in case of profound thrombocytopaenia in a patient with COVID-19.

BACKGROUND

Published data suggest that poor outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is related to an excessive inflammatory reaction.

Recent publication suggest poor outcomes in patients with coronavirus disease 2019 (COVID-19) and pre-existing advanced chronic liver disease. Only scarce information is available regarding SARS-CoV-2-related haematological disorders.

CASE PRESENTATION

We report on a 38-year-old obese patient with decompensated cirrhosis (Child–Pugh C10) and IgA nephropathy who was hospitalised on 1 April 2020 in the context of COVID-19 documented by positive PCR for SARS-CoV-2 on nasopharyngeal swab. Cirrhosis was due to alcoholic liver disease, likely aggravated by concomitant non-alcoholic steatohepatitis, and was complicated by refractory ascites since 4 months. During the 10 days preceding admission, the patient developed asthenia, fever and rapidly worsening cough associated with dyspnoea at rest. On admission, he was febrile at 39°C and had a respiratory rate of 35 per minute. The oxygen saturation was 85% while breathing ambient air and he required 6L per minute of oxygen in the context of worsening pneumonia. Chest X-ray showed the presence of bilateral peripheral airspace opacities. C reactive protein was 31 mg/L (normal range, <10 mg/L), procalcitonin 0.41 µg/L (normal range, 0.10–0.49 µg/L), ferritin 1120 µg/L (normal range, 12–300 µg/L) and D-dimers 7828 ng/mL (normal range, <500 ng/mL). The patient was treated with hydroxychloroquin (600 mg/day) and co-amoxicillin/clavulanic acid (4800 mg/day) during the first 4 days. Laboratory tests performed over the next days showed a rapid decrease of platelet count from baseline values around 70 g/L (chronic moderate thrombocytopaenia due to liver disease and hypersplenism) to a nadir of 1 x 10^9/L (figure 1). Because of severe epistaxis, platelet transfusions were administered, however with no response. A blood smear confirmed severe thrombocytopaenia and did not show any schistocytes; coagulation studies allowed to exclude disseminated intravascular coagulation (DIC), anti-platelet factor 4/heparin antibodies were not detected, testing for viral hepatitis, HIV, cytomegalovirus, Epstein–Barr virus and varicella zoster virus was negative. Hence, a diagnosis of likely SARS-CoV-2-related immune thrombocytopaenic purpura (ITP) was retained. Intravenous immunoglobulin (IVIG) (0.4 g/kg per day for 5 days) and high-dose dexamethasone (40 mg/day for 4 days) were initiated, enabling platelet count stabilisation around 30 g/L and resolution of epistaxis without any further platelet transfusion. Meanwhile, oxygen requirements (green line) decreased and the patient was well on ambient air by day 10. A secondary drop in platelet counts to 22 g/L on day 21 has motivated the administration of a second cycle of dexamethasone, resulting in return of platelet counts to baseline values.

Figure 1 Clinical course and treatments administered during hospitalisation. Platelet counts (blue line) decreased rapidly to <20 g/L. As the patient developed severe epistaxis, platelet transfusion was initiated (arrows), however without response. Due to profound thrombocytopaenia (1 g/L) and persistent epistaxis, intravenous immunoglobulin (IVIG 0.4 g/kg per day for 5 days) and dexamethasone (40 mg/day for 4 days) were administrated, enabling platelet count stabilisation around 30 g/L and resolution of epistaxis without any further platelet transfusion. Meanwhile, oxygen requirements (green line) decreased and the patient was well on ambient air by day 10. A secondary drop in platelet counts to 22 g/L on day 21 has motivated the administration of a second cycle of dexamethasone, resulting in return of platelet counts to baseline values.

OUTCOME AND FOLLOW-UP

After a transient stabilisation, platelet counts dropped again slowly to 22 g/L on day 21. Hence, a second cycle of dexamethasone (40 mg/day for 4 days) was administered and followed by a rapid increase in platelet counts to the patient’s baseline values (75 g/L at day 36). Of note, the patient

1Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
2Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Correspondence to Dr Grégoire Stalder, gregoire.stalder@chuv.ch

Accepted 28 June 2020
Indeed, the emergence of autoimmune diseases in the context of severe SARS-CoV-2 infection is increasingly reported. The differential diagnosis of thrombocytopenia in a cirrhotic patient with COVID-19 includes splenic sequestration, consumption within large thrombi, DIC and sepsis-induced thrombocytopenia. Indeed, severe SARS-CoV-2 infection is associated with coagulopathy, although thrombocytopenia is usually moderate. In this case, the kinetics of the onset of thrombocytopenia, its depth, the absence of even a transient response to platelet transfusions, the stability of coagulation parameters and the response to treatment with IVIG and dexamethasone provide reasonable evidence of an immune origin to thrombocytopenia.

Treatment with IVIG and the two cycles of dexamethasone has likely resulted in improvement of platelet counts that eventually returned to the baseline values of the patient. Importantly, the patient also experienced a favourable course of COVID-19 pneumonia. Hence, one may speculate that IVIG and dexamethasone had a beneficial impact on the excessive inflammatory reaction associated with SARS-CoV-2 infection, contributing to the favourable clinical course of the pneumonia observed in our patient. Of note, this outcome is remarkable also in light of recent data indicating an increased mortality from COVID-19 in patients with pre-existing liver disease and, notably, cirrhosis. However, more data are needed to validate this hypothesis and to assess the clinical course of COVID-19 in patients with cirrhosis as well as the incidence of ITP and the effects of its treatment in the setting of SARS-CoV-2 infection.

REFERENCES
1. Zulfiqar A-A, Lorenzo-Villalba N, Hassler P, et al. Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med 2020;382:e43.
2. Galeotti C, Barry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 2020; doi:10.1038/s41584-020-0448-7. [Epub ahead of print: 04 Jun 2020].
3. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135:2033–40.
4. Cooper N, Ghamian W. Immune thrombocytopenia. N Engl J Med 2019;381:945–55.
5. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.
6. Singh S, Khan A. Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study. Gastroenterology 2020. [Epub ahead of print: 03 May 2020].